These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1158 related items for PubMed ID: 21837481

  • 1. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [Abstract] [Full Text] [Related]

  • 2. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q, Chen J, Li HJ, Yu M, Tian CX, Lü Q.
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [Abstract] [Full Text] [Related]

  • 3. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 4. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
    Sánchez-Muñoz A, Román-Jobacho A, Pérez-Villa L, Sánchez-Rovira P, Miramón J, Pérez D, Sáez MI, de Luque V, Medina L, Ramírez-Tortosa CL, Vicioso L, Medina JA, Ribelles N, Alba E.
    Oncology; 2012 Jun; 83(4):228-33. PubMed ID: 22907070
    [Abstract] [Full Text] [Related]

  • 5. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
    Kim HJ, Han W, Yi OV, Shin HC, Ahn SK, Koh BS, Moon HG, You JH, Son BH, Ahn SH, Noh DY.
    Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P, Barbieri V, Genovesi D.
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [Abstract] [Full Text] [Related]

  • 7. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz RM.
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [Abstract] [Full Text] [Related]

  • 8. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N, Mukai H, Fujii S, Wada N.
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [Abstract] [Full Text] [Related]

  • 9. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW.
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [Abstract] [Full Text] [Related]

  • 10. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M.
    Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [Abstract] [Full Text] [Related]

  • 13. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC.
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [Abstract] [Full Text] [Related]

  • 14. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 15. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y.
    Jpn J Clin Oncol; 2012 May 01; 42(5):375-86. PubMed ID: 22450930
    [Abstract] [Full Text] [Related]

  • 16. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
    Li J, Liu X, Tong Z.
    Jpn J Clin Oncol; 2012 Jun 01; 42(6):471-6. PubMed ID: 22493058
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO, Corte MD, Junquera S, González-Fernández R, del Casar JM, García C, Andicoechea A, Vázquez J, Pérez-Fernández R, Vizoso FJ.
    Hum Pathol; 2009 Sep 01; 40(9):1224-33. PubMed ID: 19439346
    [Abstract] [Full Text] [Related]

  • 19. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.
    J Clin Oncol; 2008 May 10; 26(14):2373-8. PubMed ID: 18413639
    [Abstract] [Full Text] [Related]

  • 20. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.